RÁČIL, Zdeněk, Filip RÁZGA, Lucie BUREŠOVÁ, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Shira TIMILSINA, Petr CETKOVSKÝ and Jiří MAYER. The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. American Journal of Hematology. 2010, vol. 85, No 7, p. 525-528. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.21722. |
Other formats:
BibTeX
LaTeX
RIS
@article{966872, author = {Ráčil, Zdeněk and Rázga, Filip and Burešová, Lucie and Jurček, Tomáš and Dvořáková, Dana and Žáčková, Daniela and Timilsina, Shira and Cetkovský, Petr and Mayer, Jiří}, article_number = {7}, doi = {http://dx.doi.org/10.1002/ajh.21722}, keywords = {RESIDUAL DISEASE DETECTION; POLYMERASE-CHAIN-REACTION; CHRONIC MYELOID-LEUKEMIA; CANCER PROGRAM; OCT-1 ACTIVITY; IMATINIB; RESISTANCE; DETERMINANT; EUROPE}, language = {eng}, issn = {0361-8609}, journal = {American Journal of Hematology}, title = {The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population}, volume = {85}, year = {2010} }
TY - JOUR ID - 966872 AU - Ráčil, Zdeněk - Rázga, Filip - Burešová, Lucie - Jurček, Tomáš - Dvořáková, Dana - Žáčková, Daniela - Timilsina, Shira - Cetkovský, Petr - Mayer, Jiří PY - 2010 TI - The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population JF - American Journal of Hematology VL - 85 IS - 7 SP - 525-528 EP - 525-528 SN - 03618609 KW - RESIDUAL DISEASE DETECTION KW - POLYMERASE-CHAIN-REACTION KW - CHRONIC MYELOID-LEUKEMIA KW - CANCER PROGRAM KW - OCT-1 ACTIVITY KW - IMATINIB KW - RESISTANCE KW - DETERMINANT KW - EUROPE N2 - The monitoring of hOCT1 mRNA expression in patients with chronic myelogenous leukemia (CML) was used for predicting the response to imatinib treatment. However, different cell populations from patients who received various degrees of pretreatment were used for this analysis. Therefore, several biases in the results and their interpretation may arise. We investigated hOCT1 mRNA expression in different cell populations of peripheral blood (PB) from healthy volunteers and in imatinib nave de novo CML patients by analyzing changes in hOCT1 mRNA expression during the first 6 months of imatinib therapy. The hOCT1 mRNA expression was significantly higher in PB polymorphonuclears compared to mononuclears. The hOCT1 mRNA expression in total PB leukocytes is, therefore, preferentially determined by the percentage of polymorphonuclears. Expression in each analyzed group of cells was always significantly lower in imatinib nave de novo CML patients compared to healthy volunteers. This difference disappeared after the initiation of imatinib therapy, suggesting that CML tumor burden and the degree of pretreatment at the time of monitoring were both influencing factors. ER -
RÁČIL, Zdeněk, Filip RÁZGA, Lucie BUREŠOVÁ, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Shira TIMILSINA, Petr CETKOVSKÝ and Jiří MAYER. The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. \textit{American Journal of Hematology}. 2010, vol.~85, No~7, p.~525-528. ISSN~0361-8609. Available from: https://dx.doi.org/10.1002/ajh.21722.
|